title: Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.
authors: Departments of *Obstetrics, Gynecology, and Reproductive Science; †Pediatrics; ‡Medicine, Mount Sinai School of Medicine, New York, NY.
authors: Jessica M
authors: JM
authors: Atrio
authors: Rhoda S
authors: RS
authors: Sperling
authors: Roberto
authors: R
authors: Posada
authors: Gabriela
authors: G
authors: Rodriguez Caprio
authors: Katherine T
authors: KT
authors: Chen
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced* / Q000453:epidemiology*; D007231:Infant, Newborn; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D037841:Pregnant People; D015995:Prevalence; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
chemical_list: D019380:Anti-HIV Agents; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate